QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
NASDAQ:ALRN

Aileron Therapeutics - ALRN Stock Forecast, Price & News

$2.57
-0.09 (-3.38%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.57
$2.82
50-Day Range
$0.16
$3.40
52-Week Range
$2.51
$15.00
Volume
8,728 shs
Average Volume
30,117 shs
Market Capitalization
$11.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00

Aileron Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
61.1% Downside
$1.00 Price Target
Short Interest
Healthy
0.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.40) to ($3.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.29 out of 5 stars

Medical Sector

988th out of 1,022 stocks

Pharmaceutical Preparations Industry

480th out of 499 stocks

ALRN stock logo

About Aileron Therapeutics (NASDAQ:ALRN) Stock

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Stock News Headlines

See More Headlines
Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Company Calendar

Last Earnings
11/01/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALRN
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.00
High Stock Price Forecast
$1.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
-61.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-26,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.69 per share

Miscellaneous

Free Float
4,382,000
Market Cap
$11.67 million
Optionable
Not Optionable
Beta
1.89

Key Executives

  • Dr. Manuel C. Aivado M.D. (Age 52)
    Ph.D., Pres, CEO & Director
    Comp: $912.38k
  • Ms. Susan L. Drexler CPA (Age 52)
    M.B.A., Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. D. Allen Annis Ph.D. (Age 49)
    Sr. VP of Research













ALRN Stock - Frequently Asked Questions

Should I buy or sell Aileron Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALRN, but not buy additional shares or sell existing shares.
View ALRN analyst ratings
or view top-rated stocks.

What is Aileron Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 12 month price objectives for Aileron Therapeutics' shares. Their ALRN share price forecasts range from $1.00 to $1.00. On average, they predict the company's share price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 61.1%.
View analysts price targets for ALRN
or view top-rated stocks among Wall Street analysts.

How have ALRN shares performed in 2022?

Aileron Therapeutics' stock was trading at $0.5629 at the beginning of 2022. Since then, ALRN stock has increased by 356.6% and is now trading at $2.57.
View the best growth stocks for 2022 here
.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 12,300 shares, a decrease of 96.2% from the October 31st total of 322,000 shares. Based on an average daily trading volume, of 42,200 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the company's stock are short sold.
View Aileron Therapeutics' Short Interest
.

When is Aileron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our ALRN earnings forecast
.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) announced its earnings results on Tuesday, November, 1st. The company reported ($1.40) EPS for the quarter, beating analysts' consensus estimates of ($1.60) by $0.20.

What other stocks do shareholders of Aileron Therapeutics own?
When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (57.37%), KCK LTD. (0.49%), Renaissance Technologies LLC (4.20%) and Envestnet Asset Management Inc. (0.20%). Insiders that own company stock include Muneer A Satter, Reinhard J Ambros and Rickenbach Josef H Von.
View institutional ownership trends
.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $2.57.

How much money does Aileron Therapeutics make?

Aileron Therapeutics (NASDAQ:ALRN) has a market capitalization of $11.67 million. The company earns $-26,160,000.00 in net income (profit) each year or ($6.60) on an earnings per share basis.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The official website for the company is www.aileronrx.com. The company can be reached via phone at (617) 995-0900 or via email at hans@lifesciadvisors.com.

This page (NASDAQ:ALRN) was last updated on 12/8/2022 by MarketBeat.com Staff